Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
Cardiovascular Diabetology, 2022 Background There have been scarce data comparing cardiovascular outcomes between individual sodium-glucose cotransporter-2 (SGLT2) inhibitors. We aimed to compare the subsequent cardiovascular risk between individual SGLT2 inhibitors. Methods We analyzed
Yuta Suzuki +15 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 PurposeSodium-glucose cotransporter 2 (SGLT2) inhibitors have cardiorenal protective effects regardless of whether they are combined with type 2 diabetes mellitus, but their specific pharmacological mechanisms remain undetermined.Materials and MethodsWe ...
Anzhu Wang +13 more
doaj +1 more source
The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: A bench to bedside review [PDF]
, 2014 INTRODUCTION: The treatment of type 2 diabetes mellitus (T2DM) continues to pose challenges for clinicians and patients. The dramatic rise in T2DM prevalence, which has paralleled the rise in obesity, has strained the healthcare system and prompted the ...
McGill, Janet B
core +2 more sources
Use and effectiveness of dapagliflozin in routine clinical practice. An Italian multicenter retrospective study [PDF]
, 2018 In randomized controlled trials (RCTs), sodium-glucose co-transporter-2 (SGLT2) inhibitors have been shown to confer glycaemic and extra-glycaemic benefits.
Avogaro A +8 more
core +2 more sources
Therapeutic Advances in Chronic Disease, 2022 Objectives: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been found to reduce serum urate in patients with type 2 diabetes mellitus. To evaluate if this effect applies to both patients with and without diabetes, we conducted a systematic review
Alicia Swee Yan Yip +13 more
doaj +1 more source
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
Medicina, 2023 There is a need for innovative pharmaceutical intervention in light of the increasing prevalence of metabolic disease and cardiovascular disease. The kidneys’ sodium-glucose cotransporter 2 inhibitors (SGLT2) receptors are targeted to reduce glucose ...
Munteanu Madalina Andreea +6 more
doaj +1 more source
Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes [PDF]
, 2012 Background Despite the number of medications for type 2 diabetes, many people with the condition do not achieve good glycaemic control. Some existing glucose-lowering agents have adverse effects such as weight gain or hypoglycaemia. Type 2 diabetes tends
Clar, C. +3 more
core +1 more source
Frontiers in Pharmacology, 2021 Several large clinical trials have shown renal and cardioprotective effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors in diabetes patients, and the protective mechanisms need to be elucidated.
Kazuhiko Fukushima +3 more
doaj +1 more source
An emerging protagonist: Sodium Glucose Co-transporters (SGLTs) as a burgeoning target for the treatment of diabetes mellitus [PDF]
, 2012 Contemporary therapies to rationalize the hyperglycaemia in type 2 diabetes mellitus (T2DM) generally involve insulin-dependent mechanisms and lose their effectiveness as pancreatic b-cell function decreases to a greater extent. The kidney emerges out as
Danish Ahmed +3 more
core +2 more sources
Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus [PDF]
Diabetes & Metabolism Journal, 2021 Background Using real-world data, cardiovascular safety was investigated in metformin users newly starting sodium glucose cotransporter 2 (SGLT2) inhibitors compared with other glucose-lowering drugs in Korea.
Ja Young Jeon +2 more
doaj +1 more source